The psychedelic biotech industry is running into a regulatory wall at exactly the wrong moment.
STAT News reported Monday that paid YouTube videos promoting investigational psychedelic drugs from Helus Pharma and AtaiBeckley — a subsidiary of ATAI Life Sciences — were posted earlier this year, making claims that range from overstated to extraordinary. One video, disclosed as a paid advertisement for Helus, claimed the company had achieved "100% patient improvement in Phase 2 trials" and that "FDA may have just handed them a golden ticket." Another, paid for by a marketing agency on behalf of AtaiBeckley, said "one dose of a nasal spray could do what years of antidepressants could not, and it only takes 90 minutes." Both included disclaimers that they were for "informational purposes only" and not investment advice.
Those disclaimers do not make the claims compliant with FDA rules.
For investigational drugs — compounds that have not received FDA approval — the governing restriction is 21 CFR 312.7. It prohibits sponsors and people acting on their behalf from promoting an investigational drug as safe or effective before approval. Any paid or sponsored communication that constitutes promotion of an unapproved drug falls under this rule, regardless of disclaimers. The FDA has also made clear that it assigns promotional responsibility to drug companies for statements made by third parties, including marketing agencies and influencers acting on the company's behalf. In 2025, the agency's Office of Prescription Drug Promotion issued more enforcement letters for drug promotion violations than in any year in the previous 25 years. Nine of those letters specifically targeted celebrity and influencer spokesperson activities — including cases where the agency held companies responsible for statements made by third parties who appeared to be acting independently.
That enforcement posture is the backdrop for what STAT News reported. Helus Pharma is developing HLP003, a psilocybin-adjacent compound that received FDA Breakthrough Therapy Designation and is in two pivotal Phase 3 studies for major depressive disorder, according to Helus' own pipeline page. The company also has Phase 2 data on a DMT fumarate candidate for antidepressant potential. AtaiBeckley's lead candidate, BPL-003, received Breakthrough Therapy Designation in October 2025 and is expected to enter Phase 3 in the second quarter of 2026, pending FDA alignment. Compass Pathways, which has been running Phase 3 trials for its synthetic psilocybin candidate COMP360, is expected to file its NDA between late 2026 and 2027.
ATAI Life Sciences reported in August 2025 that it had cash to fund combined operations into the second half of 2027.
The broader context is the FDA's September 2025 enforcement announcement, which marked a significant increase in scrutiny of direct-to-consumer drug advertising. The agency issued 74 enforcement letters to pharmaceutical and biologic manufacturers in 2025 — the highest annual total in nearly 25 years. Psychedelic biotech companies with compounds in late-stage trials are operating in exactly the category the FDA has signaled it is watching.
The companies have not commented publicly on the specific videos STAT News identified.
The first FDA-approved psychedelic therapy does not exist yet.
